GenTrust’s AstraZeneca AZN Stock Holding History

GenTrust’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,171	Closed	-$284K	–	191
2024 Q4	$284K	Sell	2,171 -55	-2%	-$7.7K	0.01%	166
2024 Q3	$347K	Sell	2,226 -1,392	-38%	-$225K	0.02%	149
2024 Q2	$564K	Buy	+3,618	New	+$544K	0.03%	116

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

GenTrust's AZN Position: Q1 2025 in Review

GenTrust sold out of AstraZeneca (AZN) in Q1 2025, closing a stake of 2,171 shares — an estimated $284K sold.

GenTrust first reported a position in AZN in Q2 2024 and held it in 3 quarters. The position peaked at $564K in Q2 2024. 1,249 funds tracked by Wall St. Rank hold AZN as of Q1 2025.

GenTrust reported no remaining AstraZeneca position as of Q1 2025 after selling out during the quarter.
GenTrust sold 2,171 AstraZeneca shares in Q1 2025, an estimated $284K.
GenTrust first reported a position in AstraZeneca in Q2 2024 and held it in 3 quarters.
GenTrust's AstraZeneca position peaked at $564K in Q2 2024.
1,249 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2025.

Based on GenTrust's 13F filing for Q1 2025, filed 23 Apr 2025.